Serum Institute's 2nd COVID-19 vaccine likely to be launched in September
Serum Institute of India (SII), the world's biggest Covid-19 vaccine maker, is hopeful of launching its second vaccine for coronavirus — Covovax — by September this year, CEO Adar Poonawalla announced on Saturday.
"Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India," said Adar Poonawalla.
He further said that it has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 per cent. "Hope to launch by September 2021!" the CEO of world's biggest Covid-19 vaccine maker said.
Covovax is the protein-based Covid-19 vaccine developed by Novavax, headquartered in the US.
In August 2020, the two companies announced an agreement under which Novavax had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries.
(With IANS Inputs)
ALSO READ | Govt planning to bring more population groups under COVID-19 vaccination drive: Harsh Vardhan
ALSO READ | HC asks Serum Institute, Bharat Biotech to disclose capacity to manufacture COVID-19 vaccines
